CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Gene editing developer Scribe plots an IPO

IPO/OfferingPositive
AI Analysis

Summary

Scribe, a California-based gene editing developer with collaborations from Biogen, Sanofi, and Eli Lilly, is planning an IPO and could become the 14th biotech company to go public in 2026.

Importance:6/10
Sentiment:
0.60
gene editingIPOBiogen collaborationSanofi collaborationEli Lilly collaboration
Related Companies

Read the original article

Published by BioPharma Dive on July 6, 2026 2:45 PM

Read Original